Alnylam Pharmaceuticals, Inc. has recently released its 10-Q report, showcasing its focus on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference. The company offers a range of products, including ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. Additionally, Alnylam Pharmaceuticals is developing a robust pipeline of RNAi therapeutics, with more than 20 clinical programs, including those in late-stage development.
In its 10-Q report, Alnylam Pharmaceuticals stated that as of March 31, 2025, it had an accumulated deficit of $7.35 billion since commencing operations in 2002. The company has generated losses primarily from costs associated with research and development activities, acquiring, filing and expanding intellectual property rights, and selling, general, and administrative costs. Alnylam Pharmaceuticals aims to achieve financial self-sustainability by the end of 2025, but it anticipates incurring additional operating losses due to planned expenditures for research and development activities, including clinical trial and manufacturing costs, as well as continued build-out of late-stage clinical and commercial capabilities.
The company's worldwide product revenues are primarily derived from four commercialized products – AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, mainly in the U.S. and Europe. Alnylam Pharmaceuticals also generates a significant portion of its total revenues from collaboration revenues with partners such as Roche, Regeneron, and Novartis. The company's research and development expenses represent a substantial percentage of its total operating expenses, reflecting its broad pipeline of clinical development programs, including multiple programs in late-stage development.
Alnylam Pharmaceuticals' commercial and clinical-stage pipeline includes six approved products and multiple late and early-stage investigational RNAi therapeutics across a broad range of disease areas and indications. The company reported updates from its commercially approved products and late-stage clinical programs, including achieving global net product revenues for AMVUTTRA and ONPATTRO for the first quarter of 2025.
Following these announcements, the company's shares moved -0.5%, and are now trading at a price of $261.92. For more information, read the company's full 10-Q submission here.
